1) EAU guideline Prostate Cancer. European Association of Urology 2022 https://uroweb.org/guidelines/prostate-cancer (2022年8月1日閲覧)
2) Hamdy FC, et al : 10-Year Outcomes After Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. N Engl J Med 375 : 1415-1424, 2016
3) Chen RC, et al : Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline) : American Society of Clinical Oncology Clinical Practice Guideline Endorsement. J Clin Oncol 34 : 2182-2190, 2016
4) Mohler JL, et al : NCCN Clinical Practice Guidelines in Oncology. Prostate Cancer Version 4. 2022 https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf (2022年8月1日閲覧)
5) Shore ND, et al : Active Surveillance Plus Enzalutamide Monotherapy vs Active Surveillance Alone in Patients with Low-Risk or Intermediate-Risk Localized Prostate Cancer : The ENACT Randomized Clinical Trial. JAMA Oncol : e221641, 2022
6) Hellman S, et al : Oligometastases. J Clin Oncol 13 : 8-10, 1995
7) Gundem G, et al : The Evolutionary History of Lethal Metastatic Prostate Cancer. Nature 520 : 353-357, 2015
8) Phillips R, et al : Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer : The ORIOLE Phase 2 Randomized Clinical Trial. JAMA Oncol 6 : 650-659, 2020
9) Ost P, et al : Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence : A Prospective, Randomized, Multicenter Phase II Trial. J Clin Oncol 36 : 446-453, 2018
10) 大腸癌研究会 (編) : 大腸癌治療ガイドライン 医師用 2022年版. 金原出版, 東京, 2022
11) Selvarajan G, et al : The Continuing Conundrum in Oligometastatic Breast Carcinoma : A Real-World Data. Breast 63 : 140-148, 2022
12) 日本整形外科学会 (監), 日本整形外科学会診療ガイドライン委員会, 他 (編) : 軟部腫瘍診療ガイドライン2020改定第3版. 南江堂, 東京, 2020
13) Boevé LMS, et al : Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial : Data from the HORRAD Trial. Eur Urol 75 : 410-418, 2019
14) Parker CC, et al : Radiotherapy to the Primary Tumour for Newly Diagnosed, Metastatic Prostate Cancer (STAMPEDE) : A Randomised Controlled Phase 3 Trial. Lancet 392 : 2353-2366, 2018
15) Burdett S, et al : Prostate Radiotherapy for Metastatic Hormone-Sensitive Prostate Cancer : A STOP CAP Systematic Review and Meta-analysis. Eur Urol 76 : 115-124, 2019